Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI7SP5
|
|||
| Drug Name |
L1-79
|
|||
| Synonyms |
alpha-methylparatyrosine
Click to Show/Hide
|
|||
| Indication | Autism spectrum disorder [ICD-11: 6A02; ICD-10: F84.0; ICD-9: 299] | Phase 2 | [1] | |
| Company |
Yamo Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine 3-monooxygenase (TH) | Target Info | Inhibitor | [2] |
| BioCyc | Catecholamine biosynthesis | |||
| KEGG Pathway | Tyrosine metabolism | |||
| Metabolic pathways | ||||
| Dopaminergic synapse | ||||
| Prolactin signaling pathway | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Catecholamine Biosynthesis | |||
| Pathway Interaction Database | ATF-2 transcription factor network | |||
| AP-1 transcription factor network | ||||
| p38 signaling mediated by MAPKAP kinases | ||||
| Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| Biogenic Amine Synthesis | ||||
| Dopaminergic Neurogenesis | ||||
| Metabolism of amino acids and derivatives | ||||
| Dopamine metabolism | ||||
| Parkinsons Disease Pathway | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02947048) Safety of L1-79 in Autism. U.S. National Institutes of Health. | |||
| REF 2 | Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.